Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q26863326)
Watch
English
Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
review article
1 reference
stated in
Europe PubMed Central
title
Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions
(English)
1 reference
stated in
PubMed
main subject
iodine
1 reference
based on heuristic
inferred from title
differentiated thyroid carcinoma
1 reference
based on heuristic
inferred from title
author name string
Dadu R
series ordinal
1
1 reference
stated in
PubMed
Cabanillas ME
series ordinal
2
1 reference
stated in
PubMed
language of work or name
English
1 reference
stated in
PubMed
publication date
December 2012
1 reference
stated in
PubMed
published in
Minerva Endocrinologica: a journal on endocrine system diseases
1 reference
stated in
PubMed
volume
37
1 reference
stated in
PubMed
issue
4
1 reference
stated in
PubMed
page(s)
335-56
1 reference
stated in
PubMed
cites work
RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
21 March 2017
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
21 March 2017
Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
21 March 2017
Cancer statistics, 2012
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
21 March 2017
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
21 March 2017
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
21 March 2017
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
21 March 2017
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
21 March 2017
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
21 March 2017
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
21 March 2017
Mechanisms of angiogenesis and arteriogenesis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
7 April 2017
Skeletal-related events due to bone metastases from differentiated thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Liver resection for liver metastases from nondigestive endocrine cancer: extrahepatic disease burden defines outcome
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Stereotactic radiosurgery in the management of brain metastases from primary thyroid cancers.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Molecularly targeted therapies for thyroid cancers.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Phase II trial of sorafenib in metastatic thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Motesanib diphosphate in progressive differentiated thyroid cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Phase II trial of sorafenib in advanced thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
External beam radiation therapy for thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Bone metastases from differentiated thyroid carcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
The role of radiation therapy in the management of thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
We should desist using RECIST, at least in GIST.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
The role of external beam radiotherapy in the treatment of papillary thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Chemoembolization for liver metastases from medullary thyroid carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
BRAF mutation in thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Solitary liver metastasis from Hürthle cell thyroid cancer: a case report and review of the literature
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 September 2017
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
31 May 2018
Prognosis and treatment of brain metastases in thyroid carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
31 May 2018
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
A phase II study of gefitinib in patients with advanced thyroid cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
Survival and death causes in differentiated thyroid carcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980664
retrieved
28 November 2018
Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23235190
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23235190
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23235190
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Presence of BRAF V600E in very early stages of papillary thyroid carcinoma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23235190
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Thyroid carcinoma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23235190
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23235190
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Gamma knife radiosurgery for metastatic brain tumors from thyroid cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23235190
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23235190
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Radiofrequency ablation of hepatic metastases from thyroid carcinoma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23235190
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23235190
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23235190
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23235190
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23235190
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
OpenCitations bibliographic resource ID
1201861
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1201861
PMC publication ID
3980664
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1201861
PubMed publication ID
23235190
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1201861
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
